Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug;55(8):1525-1532.
doi: 10.1038/s41409-020-0892-7. Epub 2020 Apr 18.

CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview

Mohamad Mohty  1 , Remy Dulery  2 , Jordan Gauthier  3   4 , Florent Malard  2 , Eolia Brissot  2 , Mahmoud Aljurf  5 , Ali Bazarbachi  6 , Christian Chabanon  7 , Mohamed A Kharfan-Dabaja  8 , Bipin N Savani  9 , He Huang  10 , Saad S Kenderian  11 , Miguel-Angel Perales  12   13 , Ibrahim Yakoub-Agha  14 , Arnon Nagler  15
Affiliations
Review

CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview

Mohamad Mohty et al. Bone Marrow Transplant. 2020 Aug.

Abstract

The goal of this review is to firstly address the concept of chimeric antigen receptor T-cell (CAR T-cell) therapy and where it fits in the evolving landscape of the management of patients with refractory/relapsed diffuse large B-cell lymphoma. The recognition of the indications for CAR T-cell therapy for patients with aggressive B-cell lymphoma will be discussed, including a review of the algorithms and selection criteria for CAR T-cell therapy and finally, the role of bridging therapy and the timing of CAR T-cell therapy in augmenting chances of a successful outcome.

PubMed Disclaimer

References

    1. Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105–16. - DOI - PubMed
    1. Pfreundschuh M, Kuhnt E, Trumper L, Osterborg A, Trneny M, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12:1013–22. - PubMed
    1. Schmitz N, Nickelsen M, Ziepert M, Haenel M, Borchmann P, Schmidt C, et al. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol. 2012;13:1250–9. - DOI - PubMed
    1. Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematol Am Soc Hematol Educ Program. 2011;2011:498–505. - DOI
    1. Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, et al. Diffuse large B-cell lymphoma version 1.2016. J Natl Compr Canc Netw. 2016;14:196–231. - DOI - PubMed

LinkOut - more resources